PUBLISHER: The Business Research Company | PRODUCT CODE: 1942795
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942795
Electronic drug delivery systems encompass devices or formulations designed to facilitate the targeted delivery of a medical substance to a specific region while avoiding non-target cells and tissues. These systems ensure the controlled administration of drugs, allowing for easy monitoring of doses.
The primary categories of electronic drug delivery systems include electronic infusion pumps, electronic injection pens, electronic auto-injectors, electronic inhalers, electronic capsules, and other variants. Electronic infusion pumps are medical devices that regulate the controlled delivery of fluids into a patient's body. Deployed in healthcare settings such as hospitals and nursing homes, these pumps are instrumental in delivering fluids such as nutrients and medications. Essential components of electronic drug delivery systems comprise sensors, wireless communicators, antennas, micro-pumps, flow regulators, drug reservoirs, microcontrollers, and other elements, available in both battery-powered and rechargeable systems. These electronic drug delivery systems are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, catering to the treatment of various conditions such as diabetes, cardiovascular disease, respiratory disorders, multiple sclerosis, and other ailments.
Tariffs are impacting the electronic drug delivery systems market by increasing costs of imported sensors, microcontrollers, batteries, wireless modules, and precision pumps used in smart delivery devices. Pharmaceutical and medical device manufacturers in North America and Europe are most affected due to reliance on imported electronic components, while Asia-Pacific faces cost pressure on device assembly. These tariffs are increasing production costs and device pricing. However, they are also encouraging domestic component sourcing, local assembly, and innovation in cost-efficient electronic drug delivery solutions.
The electronic drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides electronic drug delivery systems market statistics, including electronic drug delivery systems industry global market size, regional shares, competitors with a electronic drug delivery systems market share, detailed electronic drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the electronic drug delivery systems industry. This electronic drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The electronic drug delivery systems market size has grown strongly in recent years. It will grow from $11.93 billion in 2025 to $13.11 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, expansion of injectable and inhalable therapies, increasing use of infusion-based treatments, growth in home healthcare adoption, availability of electronic drug delivery platforms.
The electronic drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $19.44 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing demand for personalized drug delivery, rising adoption of digital health ecosystems, expansion of remote patient monitoring, growing focus on adherence-driven outcomes, increasing integration of ai-based dosing algorithms. Major trends in the forecast period include increasing adoption of smart drug delivery devices, rising integration of connected and wearable delivery systems, growing use of precision dose control technologies, expansion of patient-centric self-administration devices, enhanced focus on therapy adherence monitoring.
The anticipated growth of the electronic drug delivery systems market is expected to be driven by the increasing prevalence of chronic diseases. Chronic diseases, lasting for more than a year and necessitating ongoing medical treatment, can benefit from electronic drug delivery systems that aid in regulating and monitoring drug doses. For example, in January 2023, the National Library of Medicine reported that the number of individuals in the US aged 50 and older with at least one chronic condition is projected to reach 142.66 million by 2050. This upward trend in chronic diseases is poised to fuel the demand for electronic drug delivery systems.
Major companies in the electronic drug delivery systems market are increasingly focusing on innovative solutions, such as reusable electronic injector platforms, to improve dosing accuracy, patient adherence, and sustainability. Reusable electronic injector platforms are battery-powered, smart devices designed for multiple uses, delivering precise medication doses while tracking usage and supporting adherence. For example, in January 2025, Portal Instruments Inc., a US-based medical device company, launched the PRIME Nexus, a reusable electronic injector platform engineered to enhance the administration of injectable medications with improved precision, versatility, and sustainability. The system accommodates multiple drug container sizes, including 1 mL and 2.25 mL pre-filled syringes and 3 mL cartridges, and can handle high-viscosity formulations up to 600 cP. It provides programmable injection control and optional connectivity for adherence monitoring and data sharing with healthcare providers. Its reusable design supports sustainability by reducing medical waste and lowering overall injection costs.
In November 2025, Biogen Inc., a US-based biotechnology company, acquired Alcyone Therapeutics for an undisclosed amount. Through this acquisition, Biogen aims to strengthen its central nervous system (CNS) drug delivery capabilities and expand its pipeline of targeted therapies. Alcyone Therapeutics Inc., a US-based healthcare technology company, specializes in developing advanced drug delivery platforms designed to enhance precision and efficacy in the treatment of neurological disorders.
Major companies operating in the electronic drug delivery systems market are Medtronic plc, Novo Nordisk A/S, Insulet Corporation, Tandem Diabetes Care Inc., United Therapeutics Corporation, Sanofi S.A., Abbott Laboratories, Roche Holding AG, Johnson & Johnson, Bayer AG, Antares Pharma Inc., CeQur Corporation, BIOCORP, Adherium Limited, Amiko Digital Health Limited, FindAir Sp. z o.o., HCmed Innovations Co. Ltd., Insulet International Limited, Ypsomed Holding AG, Enable Injections Inc., Eitan Medical Ltd.
North America was the largest region in the electronic drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global electronic drug delivery systems market report during the forecast period. The regions covered in the electronic drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the electronic drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The electronic drug delivery systems market consists of sales of nasal sprays, eyedroppers, and intrauterine devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Electronic Drug Delivery Systems Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses electronic drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for electronic drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The electronic drug delivery systems market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.